Toxoplasmosis is a parasite that can cause serious infection in humans. Symptoms include diarrhea, abdominal pain, rash, and fever. Toxoplasmosis is often caused by an insect bite, but the disease can also affect the eyes and central nervous system. It can cause inflammation of the uvea and retina as well as the anterior chamber of the eye. It can also cause an abnormal pupil size. In severe cases, toxoplasmosis can cause blindness and affect coordination, heightened sensitivity to touch, and circling.
The global toxoplasmosis treatment drugs market is estimated to be valued at US$ 2,859.4 million in 2020 and is expected to exhibit a CAGR of 4.9% during the forecast period (2020-2027).
Get Free Sample PDF Copy (Including Full TOC, List of Tables & Figures, Chart) @
The growing prevalence of chronic diseases which may lead to toxoplasmosis infection is driving growth of the global toxoplasmosis treatment drugs market
Growing prevalence of cancer and increasing chemotherapy procedures which may lead to toxoplasmosis infection is expected to drive the toxoplasmosis treatment drugs market growth. According to Cancer Research U.K., factsheet around 17 million people were diagnosed with cancer in 2018.
According to the same source, the cancer type and new cancer cases in 2018 globally are as follows.
|Rank||Cancer Type||New Cases Diagnosed in 2018|
Increasing number of toxoplasmosis cases is the key factor augmenting the toxoplasmosis treatment drugs market over the forecast period. According to the World Health Organization estimates – Foodborne Disease Burden Epidemiology Reference Group 2007-2015, the global number of Toxoplasma gondii infection are as follows
- Foodborne Illnesses: 10,280, 089
- Foodborne Deaths: 684
- Foodborne Years Lived with Disability (YLDs): 7,63,326
- Foodborne Years of Life Lost (YLLs): 62,899
- Foodborne Disability Adjusted Life Years (DALYs): 8,29,071
On the other hand, side effects of drugs such as pyrimethamine used in treatment of Toxoplasmosis include hypersensitivity reactions that can occasionally be severe, including Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, and hyperphenylalaninemina is expected to hamper the market growth. Additionally, the drugs used in toxoplasmosis treatment may produce megaloblastic anemia, leukopenia, thrombocytopenia, pancytopenia, neutropenia, atrophic glossitis, hematuria, and disorders of cardiac rhythm.
High cost of drugs used in the treatment of toxoplasmosis is the key factor restraining the global toxoplasmosis treatment drugs market over the forecast period. For instance, the price of Daraprim is very high – with the list price for one month supply (60 tablets) was nearly US$ 45,000 in 2018 in the U.S.
Request PDF Brochure with Latest Insights @
The coronavirus (COVID-19) pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare is one such sector which has been impacted significantly by the COVID-19 pandemic. The lockdown in various countries due to the pandemic has placed an economic burden on the healthcare sector.
Moreover, the coronavirus pandemic has hampered the development, production, and supply of drugs and other healthcare products and affected growth of healthcare businesses of various companies across the globe.
As a result, the impact of the COVID-19 pandemic is also expected to limit growth of the global toxoplasmosis treatment drugs market during the forecast period.
Many researchers has started studying to determine the link between COVID-19 and toxoplasmosis. For instance, in May 2020, the scientist from the University of Szczecin, the University of Life Sciences in Pozna? and their colleagues from Hungary, France, and China studied and determined whether there was any link between COVID-19 cases and toxoplasmosis spread by cats and by the protozoan Toxoplasma gondii. The scientist concluded that the interactions between many pathogens can influence the emergence of various diseases and an analysis of toxoplasmosis and coronavirus data from 86 countries showed that most cases of the parasitic disease coincided with a slower spread of COVID-19.
Major players operating in the global toxoplasmosis treatment drugs market are Vyera Pharmaceuticals LLC, Taj Accura Pharmaceuticals Ltd., Mangalam Drugs and Organics Ltd., Cerovene Healthcare PVT LTD, Greenstone LLC, Amneal Pharmaceuticals, Inc., Turing Pharmaceuticals, F. Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd., and Baxter International Inc.
Reasons to buy this Toxoplasmosis Treatment Drugs Market Report
◘ Save time carrying out entry-level research by identifying the size, growth, and leading players in the emerging Toxoplasmosis Treatment Drugs Market
◘ Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the emerging Toxoplasmosis Treatment Drugs Market
◘ Leading company profiles reveal details of key Toxoplasmosis Treatment Drugs Market players emerging five operations and financial performance
◘ Add weight to presentations and pitches by understanding the future growth prospects of the emerging Toxoplasmosis Treatment Drugs Market with five year historical forecasts
◘ Compares data from North America, South America, Asia Pacific Europe and Middle East Africa, alongside individual chapters on each region
The next part also sheds light on the gap between supply and consumption. Apart from the mentioned information, growth rate of Toxoplasmosis Treatment Drugs Market in 2028 is also explained. Additionally, type wise and application wise consumption tables and figures of Toxoplasmosis Treatment Drugs Market are also given.
𝐁𝐮𝐲 𝐓𝐡𝐢𝐬 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐖𝐢𝐭𝐡 𝐅𝐥𝐚𝐭 𝐔𝐒𝐃 𝟐𝟎𝟎𝟎 𝐎𝐟𝐟 @
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Toxoplasmosis Treatment Drugs Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Toxoplasmosis Treatment Drugs Industry Impact
Chapter 2 Global Toxoplasmosis Treatment Drugs Competition by Types, Applications, and Top Regions and Countries
2.1 Global Toxoplasmosis Treatment Drugs (Volume and Value) by Type
2.3 Global Toxoplasmosis Treatment Drugs (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Toxoplasmosis Treatment Drugs Sales, Consumption, Export, Import by Regions
Chapter 5 North America Toxoplasmosis Treatment Drugs Market Analysis
Chapter 6 East Asia Toxoplasmosis Treatment Drugs Market Analysis
Chapter 7 Europe Toxoplasmosis Treatment Drugs Market Analysis
Chapter 8 South Asia Toxoplasmosis Treatment Drugs Market Analysis
Chapter 9 Southeast Asia Toxoplasmosis Treatment Drugs Market Analysis
Chapter 10 Middle East Toxoplasmosis Treatment Drugs Market Analysis
Chapter 11 Africa Toxoplasmosis Treatment Drugs Market Analysis
Chapter 12 Oceania Toxoplasmosis Treatment Drugs Market Analysis
Chapter 13 South America Toxoplasmosis Treatment Drugs Market Analysis
Chapter 14 Company Profiles and Key Figures in Toxoplasmosis Treatment Drugs Business
Chapter 15 Global Toxoplasmosis Treatment Drugs Market Forecast (2022-2028)
Chapter 16 Conclusions
About Coherent Market Insights
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027